文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2018 年美国心脏病学会/美国心脏协会/美国心血管血管造影和介入学会/美国预防、物理治疗和康复医师学会/美国糖尿病协会/美国老年学会/美国药学会/美国医师协会/美国生理学会/北美介入放射学会/美国国家脂质协会/美国临床内分泌医师协会胆固醇管理指南:美国心脏病学会/美国心脏协会临床实践指南工作组的报告。

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

机构信息

ACC/AHA Representative. †AACVPR Representative. ‡ACC/AHA Task Force on Clinical Practice Guidelines Liaison. §Prevention Subcommittee Liaison. ‖PCNA Representative. ¶AAPA Representative. **AGS Representative. ††ADA Representative. ‡‡PM Representative. §§ACPM Representative. ‖‖NLA Representative. ¶¶APhA Representative. ***ASPC Representative. †††ABC Representative.

出版信息

Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10.


DOI:10.1161/CIR.0000000000000625
PMID:30586774
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/
Abstract

Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a foundation for the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and publication of clinical practice guidelines without commercial support, and members volunteer their time to the writing and review efforts. Clinical practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease (CVD). The focus is on medical practice in the United States, but these guidelines are relevant to patients throughout the world. Although guidelines may be used to inform regulatory or payer decisions, the intent is to improve quality of care and align with patients’ interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances, and should not replace clinical judgment. Recommendations for guideline-directed management and therapy, which encompasses clinical evaluation, diagnostic testing, and both pharmacological and procedural treatments, are effective only when followed by both practitioners and patients. Adherence to recommendations can be enhanced by shared decision-making between clinicians and patients, with patient engagement in selecting interventions on the basis of individual values, preferences, and associated conditions and comorbidities. The ACC/AHA Task Force on Clinical Practice Guidelines strives to ensure that the guideline writing committee both contains requisite expertise and is representative of the broader medical community by selecting experts from a broad array of backgrounds, representing different geographic regions, sexes, races, ethnicities, intellectual perspectives/biases, and scopes of clinical practice, and by inviting organizations and professional societies with related interests and expertise to participate as partners or collaborators. The ACC and AHA have rigorous policies and methods to ensure that documents are developed without bias or improper influence. The complete policy on relationships with industry and other entities (RWI) can be found online. Beginning in 2017, numerous modifications to the guidelines have been and continue to be implemented to make guidelines shorter and enhance “user friendliness.” Guidelines are written and presented in a modular knowledge chunk format, in which each chunk includes a table of recommendations, a brief synopsis, recommendation-specific supportive text and, when appropriate, flow diagrams or additional tables. Hyperlinked references are provided for each modular knowledge chunk to facilitate quick access and review. More structured guidelines–including word limits (“targets”) and a web guideline supplement for useful but noncritical tables and figures–are 2 such changes. This Preamble is an abbreviated version, with the detailed version available online. The reader is encouraged to consult the full-text guideline for additional guidance and details, since the executive summary contains mainly the recommendations.

摘要

自 1980 年以来,美国心脏病学会 (ACC) 和美国心脏协会 (AHA) 一直致力于将科学证据转化为临床实践指南,提出改善心血管健康的建议。这些指南基于评估和分类证据的系统方法,为提供高质量的心血管护理提供了基础。ACC 和 AHA 没有商业支持赞助临床实践指南的制定和发布,成员们自愿投入时间参与写作和审查工作。临床实践指南提供适用于患有或有发展为心血管疾病 (CVD) 风险的患者的建议。重点是美国的医疗实践,但这些指南与世界各地的患者都有关。尽管指南可能用于为监管或支付者的决策提供信息,但目的是改善护理质量并符合患者的利益。指南旨在定义在大多数情况下满足患者需求的实践,但并非所有情况下都适用,并且不应替代临床判断。指南指导的管理和治疗建议涵盖临床评估、诊断测试以及药物和程序治疗,只有在医生和患者都遵循的情况下才有效。通过临床医生和患者之间的共同决策,可以增强对建议的遵守,让患者根据个人价值观、偏好以及相关情况和合并症来选择干预措施。ACC/AHA 临床实践指南工作组努力确保指南写作委员会既具备必要的专业知识,又通过从广泛的背景中选择专家、代表更广泛的医学界,代表不同的地理区域、性别、种族、族裔、知识观点/偏见以及临床实践范围,并邀请具有相关利益和专业知识的组织和专业协会作为合作伙伴或合作者,来确保委员会的代表性。ACC 和 AHA 有严格的政策和方法来确保文件的制定没有偏见或不当影响。完整的行业和其他实体关系政策 (RWI) 可在线获取。自 2017 年以来,对指南进行了多项修改,并将继续进行修改,以缩短指南并增强“用户友好性”。指南以模块化知识块的格式编写和呈现,每个模块都包含一个推荐表、一个简短的概要、推荐特定的支持文本,以及在适当情况下,流程图或其他表格。为每个模块化知识块提供超链接参考,以方便快速访问和审查。更具结构性的指南——包括字数限制(“目标”)和用于有用但非关键表格和图表的网络指南补充——是这两种变化中的两种。这篇前言是一个缩写版本,完整版本可在线获取。读者被鼓励查阅全文指南以获取更多指导和详细信息,因为执行摘要主要包含建议。

相似文献

[1]
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Circulation. 2018-11-10

[2]
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Circulation. 2019-6-18

[3]
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Circulation. 2018-11-10

[4]
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

J Am Coll Cardiol. 2018-11-10

[5]
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

J Am Coll Cardiol. 2019-6-25

[6]
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

J Am Coll Cardiol. 2019-6-25

[7]
Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol.

Am J Cardiovasc Drugs. 2020-2

[8]
The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes.

Diabetes Care. 2020-8

[9]
The New 2018 Cholesterol Guidelines.

Circulation. 2019-6-18

[10]
Correction to: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Circulation. 2023-8-15

引用本文的文献

[1]
Comparison of Artificial Intelligence Models and Human Experts in Managing Dyslipidemia: Assessment of Adherence to Clinical Guidelines.

Cureus. 2025-8-31

[2]
The Gulliver syndrome: a conceptual framework to address therapeutic inertia in patients with borderline cardiovascular risk profiles.

Front Cardiovasc Med. 2025-8-14

[3]
Real-world prescribing in accordance to ACC/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD: Real-World Prescribing for Lipid-Lowering Therapy.

Am J Prev Cardiol. 2025-7-23

[4]
Skeletal Muscle and Cardiovascular Health.

Adv Exp Med Biol. 2025

[5]
Prognostic Implication of LDL-C Variability and Its Association with Lipid-Lowering Strategies: Insights from the RACING and LODESTAR Trials.

Yonsei Med J. 2025-9

[6]
Violence in Healthcare Workers Is Associated with Disordered Eating.

Int J Environ Res Public Health. 2025-8-5

[7]
A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part I.

Life (Basel). 2025-7-25

[8]
Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis.

J Health Popul Nutr. 2025-8-26

[9]
Assessment of the Utilization of Lipoprotein (a) and its Relationship with Cardiovascular Outcomes: A Retrospective Cohort Study from a Public Hospital in New York City.

Heart Views. 2025

[10]
Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial.

Crit Pathw Cardiol. 2025-9-1

本文引用的文献

[1]
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Circulation. 2018-11-10

[2]
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

N Engl J Med. 2018-11-7

[3]
Coronary Calcium Score and Cardiovascular Risk.

J Am Coll Cardiol. 2018-7-24

[4]
Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90.

N Engl J Med. 2018-6-21

[5]
Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials.

Prog Cardiovasc Dis. 2018-5-26

[6]
Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association.

Circulation. 2018-5-24

[7]
Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA).

Eur Heart J. 2018-7-1

[8]
The Psychology of Clinical Decision Making - Implications for Medication Use.

N Engl J Med. 2018-2-22

[9]
PCSK9 Inhibitors: Economics and Policy.

J Am Coll Cardiol. 2017-11-28

[10]
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).

Circulation. 2017-11-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索